A pre-clinical study for chronic lymphocytic leukemia similarly finds that NKG2A is suppressed by Monalizumab (a mAb against NKG2A), resulting in overall enhancement of anti-leukemia activities (45). The gene discussed is KLRC1; the disease is B-cell chronic lymphocytic leukemia.